Oxford, UK – 20 November 2012. OGT, provider of innovative genetics research and biomarker solutions to advance molecular medicine, announced today that it has opened a new office in Tarrytown, New York to support and grow its CytoSure® cytogenetics research arrays and Genefficiency™ next generation sequencing business in the US.
The new office will enable OGT to provide hands-on technical support and training to its existing US customers, and to take advantage of opportunities to develop the business further. A number of Sales and Support positions including a Field Application Specialist have been created with more new roles expected in the coming months.
OGT has CytoSure and Genefficiency customers in over 30 countries worldwide and serves a potential cytogenetics market of $400 million* with rapid future growth forecast. The US is the world’s largest cytogenetics market, and is critical to the development of OGT’s genomic solutions business.
Dr Mike Evans, CEO at OGT said, “The opening of the New York office marks a significant milestone for OGT allowing us to offer our US customers even better technical and sales support. Meeting the needs of our customers is our top priority, in a recent survey, 100% of our CytoSure customers said they would recommend OGT to a colleague and we are committed to both continuing and building on this level of expertise and support”.
Dr Madhuri Hegde from Emory University School of Medicine said, “We are delighted that OGT has opened a new US office. The company has a strong reputation and we have always received exceptional service, we look forward to working with the new local support team.”
CytoSure products and Genefficiency services combine advanced microarray and sequencing solutions with class-leading analysis software, enabling researchers to accurately detect and interpret chromosomal abnormalities. The CytoSure range focuses on constitutional genetics, molecular genetics and cancer cytogenetics and is a strong growth area for OGT with an increasing global market share.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
Launch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.Read
Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.Read